NEW YORK (GenomeWeb News) – NextBio today announced a deal with the Winship Cancer Institute of Emory University to identify biomarkers and treatments for multiple myeloma.

The organizations will collaborate on a translational study using NextBio Clinical to interpret molecular data from patients with the disease, which constitutes only about 1 percent of all cancers in the US but has been especially difficult to treat. The goal of the study will be to make new discoveries that can improve care given to patients with refractory and relapsed forms of myeloma, NextBio said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.